Obermatt
See Similar Stocks →

TherapeuticsMD

NSQ:TXMD · US88338N2062
PharmaceuticalsX-Small

360

34
Medium confidence — indicative
Profit price—
Owner Earnings Yield74
Dividend Yield1
Price/Sales37
EV / Gross Profit19
Price/Book92
Return on Capital49
Return on Equity66
EBIT Margin4
Gross Profitability28

Cash truth not applicable for financial companies.

Sales growth85
Profit growth50
Reinvestment35
Price momentum59
Debt load51
Debt serviceability86
Liquidity17
Analyst ratings1
Expectations trend50
Market mood4
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

TherapeuticsMD clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryUSA
IndustryPharmaceuticals
SizeX-Small
TypePublic Company
ExchangeNASDAQGS
Employees53
Websitetherapeuticsmd.com
ISINUS88338N2062
Last UpdateApr 2, 2026
Index & Theme
Women's HealthReproductive HealthNutraceuticalBiotechnologyHealth CareMedicalPharmaceutical

Description

TherapeuticsMD, Inc. (TherapeuticsMD) operates as a pharmaceutical royalty company. The company is substantially dependent on the sales forces of its licensees to attract new business and to manage existing customer relationships. The company is re…

Analysis

Middle-of-the-road

TherapeuticsMD, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is mixed; the safety picture is stretched. The company scores 10/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
33
2023202420252026

All-time high

85

Mar 2026

All-time low

11

Jan 2025

Average rank

36

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
37
17
26
82
Price/Earnings
78
77
90
46
Price/Book
92
83
61
94
Dividend Yield
1
1
1
1
Value (overall)
87
45
57
83

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare TherapeuticsMD with its peers
Knight Therapeutics
TOR:GUD
93
CountryCanada
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Oramed Pharmaceuticals
NAQ:ORMP
47
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Aquestive Therapeutics
NMQ:AQST
41
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Journey Medical Corporation
NAQ:DERM
73
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
MIRA Pharmaceuticals
NAQ:MIRA
—
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Structure Therapeutics
NMQ:GPCR
67
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →